1.
ClinicalTrials.gov; 06/02/2024; TrialID: NCT06248151
Clinical Trial Register
| ICTRP | ID: ictrp-NCT06248151
ABSTRACT
Condition:
Post-Acute COVID-19 SyndromeIntervention:
Behavioral: Exercise session;Behavioral: Control sessionPrimary outcome:
Change in Blood pressure;Change in Heart rate variability;Change in flow mediated dilation;Change in peak exhalation flow;Change in oxygen saturationCriteria:
Inclusion Criteria:
Post-Covid Syndrome group:
- have had a positive RT-PCR test for Covid-19;
- present persistent symptoms of Post Covid 19 syndrome, which have no other health
explanation according to the criteria of the World Health Organization (WHO);
- have the cognitive and physical capacity to perform the exercises; It is
- low cardiovascular risk classification according to the American College of Sports
Medicine criteria.
Healthy group:
- not present persistent symptoms of Post Covid 19 syndrome, which have no other health
explanation according to the criteria of the World Health Organization (WHO);
- have the cognitive and physical capacity to perform the exercises; It is
- low cardiovascular risk classification according to the American College of Sports
Medicine criteria.
2.
ClinicalTrials.gov; 12/12/2023; TrialID: NCT06168006
Clinical Trial Register
| ICTRP | ID: ictrp-NCT06168006
ABSTRACT
Condition:
Post-Acute COVID-19 SyndromeIntervention:
Behavioral: Exercise;Behavioral: ControlPrimary outcome:
Change from baseline in 6 min-walk test distance at 12 weeks;Change from baseline in Glittre test at 12 weeks;Change from baseline in sit and stand test at 12 weeks;Change from baseline in Post-Covid Functional Scale at 12 weeksCriteria:
Inclusion Criteria:
- Laboratory diagnosis of COVID-19
- Fatigue = 8 points on the Chalder Scale and/or dyspnea 2-4 on the Modified Medical
Research Council
- Have access to a smartphone
- Have no contraindications for exercise practice
- Have ability to sit and stand and maintain balance while standing
- Have preserved cognitive function
- Have no risk of falls according to the Morse Fall Scale
3.
ClinicalTrials.gov; 20/09/2022; TrialID: NCT05760092
Clinical Trial Register
| ICTRP | ID: ictrp-NCT05760092
ABSTRACT
Condition:
Xerostomia;COVID-19;Long COVID;Persistent COVID-19Intervention:
Combination Product: Institutional standard treatment for xerostomia and Long Covid;Radiation: Photobiomodulation Therapy;Radiation: Placebo Photobiomodulation TherapyPrimary outcome:
Brazilian version of the SF 36 Quality of Life Scale;Nutritional assessment;Salivary ph, Stimulated salivary flow and unstimulated salivary flow;Oral Health Impact Profile (OHIP-14);Xerostomia Inventory XI;Functional Independence Measure (FIM);Post-Covid-19 Functional Status Scale;The World Health Organization Disability Assessment Schedule (WHODAS 2.0)Criteria:
Inclusion Criteria:
- Clinical diagnosis xerostomia related to Long-COVID;
- more than 4 weeks after the acute infection hat have persisted for at least 02 months
(regardless of whether these patients are already using treatment for the complaints
or not);
- Age greater than 18 years.
Exclusion Criteria:
- Clinical diagnosis of other previous rheumatological or musculoskeletal diseases that
presents xerostomia;
- Previous use in the last 90 days of laser treatment or other photobiomodulation
technique for the same or another indication;
- Clinical manifestations or complaints of xerostomia related to diseases other than
Long COVID;
- Previous diseases of the oral or nasal cavity that occur with the symptom of
xerostomia;
- Systemic inflammatory diseases (rheumatoid arthritis, Reiter's arthritis, ankylosing
spondylitis, generalized polyarthritis, neoplasms);
- Uncontrolled metabolic or endocrine diseases;
- Neoplastic diseases;
- Serious cognitive or psychiatric disorders that that do not allow the understanding of
the study;
- Steroid injections during the last 48 hours prior to baseline study assessment;
- Use of corticosteroids at an immunosuppressive dose (20mg daily of prednisone or
equivalent for at least 14 days);
- Infection or tumor at the site of therapy application;
- Current chronic infections such as tuberculosis or chronic hepatitis treated or not;
- Severe blood dyscrasia;
- Blood clotting disorders (including thrombosis) at the application site;
- Psychoaffective disorder that prevents adherence to treatment;
- Signs, symptoms or laboratory changes suggestive of acute reinfection by COVID 19;
- Elevated resting heart rate (>100 beats/min);
- Low or high blood pressure (<90/60 or >140/90 mmHg);
- Low blood oxygen saturation (<95%) at rest, or dyspnea grade 3, 4, or 5 on the Medical
Research Council Dyspnea Scale (KOVELIS et al., 2008), or exacerbation of dyspnea on
exertion;
- Any condition where exercise is a contraindication such as decompensated heart
disease, decompensated diabetes;
- Contraindications to the rehabilitation treatment of post-COVID syndrome recommended
by the WHO: presence of heart disease after acute COVID, decrease in blood oxygen
saturation after exercise (below 94% or decrease of at least 3% of the baseline
saturation), presence of orthostatic hypotension;
- Any photosensitive disease or light sensitivity condition;
- Loss of follow-up at the follow-up clinical outpatient clinic, despite maintaining use
of PBM according to the study protocol;
- Pregnancy;
- Any adverse effect on the previous use of PBM.
4.
ClinicalTrials.gov; 22/06/2022; TrialID: NCT05430776
Clinical Trial Register
| ICTRP | ID: ictrp-NCT05430776
5.
ClinicalTrials.gov; 18/01/2021; TrialID: NCT04716426
Clinical Trial Register
| ICTRP | ID: ictrp-NCT04716426
ABSTRACT
Condition:
COVID-19Intervention:
Drug: Tetracycline hydrochloride 3%;Drug: PlaceboPrimary outcome:
COVID-19 Contamination Rate.Criteria:
Inclusion Criteria:
- good general health (without serious health problems);
- tested negative, by means of immunoglobulin (Ig) G and IgM serology tests and chain
real-time polymerase chain reaction (RT-PCR), for COVID-19.
Exclusion Criteria:
- previous immunization against COVID-19;
- allergy to tetracycline hydrochloride;
- diagnosis of Lyme disease;
- immunocompromised;
- share housing with someone diagnosed with COVID-19 at the time of the baseline
evaluation;
- serious illnesses, such as cancer, kidney failure, decompensated cardiorespiratory and
metabolic diseases, etc.
6.
ClinicalTrials.gov; 08/05/2020; TrialID: NCT04386694
Clinical Trial Register
| ICTRP | ID: ictrp-NCT04386694
ABSTRACT
Condition:
COVID-19;Respiratory FailureIntervention:
Device: Active PBMT/sMF;Device: Placebo PBMT/sMFPrimary outcome:
Time until dischargeCriteria:
Inclusion Criteria:
- Patients admitted to the adult Intensive Care Unit with Covid-19 infection;
- Need for orotracheal intubation;
- Invasive mechanical ventilation due to respiratory failure.
Exclusion Criteria:
- Suspected patients who had a negative result of the diagnostic examination for
COVID-19 infection;
- Patients positioned in pronation for more than 24 hours;
- Cancer patients;
- Pregnancy.